

**eTable 2. Primary and secondary outcome adverse event rates, by vaccine brand<sup>a</sup>**

Adverse event <sup>b</sup>	Afluria Quad	Fluarix Tetra	FluQuadri	FluQuadri Junior
<i>Any event</i>	316/4,857 (6.5)	1,965/33,467 (5.9)	2,250/31,225 (7.2)	336/4,147 (8.1)
<i>Fever</i>	32/4,679 (0.7)	268/32,420 (0.8)	317/30,136 (1.1)	96/4,016 (2.4)
<i>Medical attention</i>	20/4,857 (0.4)	138/33,467 (0.4)	121/31,225 (0.4)	46/4,147 (1.1)
<i>Pain at the injection site</i>	70/4,679 (1.5)	460/32,420 (1.4)	646/30,136 (2.1)	48/4,016 (1.2)
<i>Tired/fatigued<sup>c</sup></i>	55/4,618 (1.2)	422/31,974 (1.3)	488/29,875 (1.6)	50/3,757 (1.3)
<i>Swelling and/or redness at the injection site<sup>d</sup></i>	59/4,624 (1.3)	350/32,062 (1.1)	474/30,030 (1.6)	47/4,012 (1.2)
<i>Headache<sup>c</sup></i>	50/4,614 (1.1)	298/31,967 (0.9)	371/29,868 (1.2)	2/3,755 (0.1)
<i>Sleep pattern change<sup>c</sup></i>	15/4,614 (0.3)	121/31,938 (0.4)	171/29,850 (0.6)	41/3,756 (1.1)
<i>Irritable<sup>c</sup></i>	17/4,613 (0.4)	91/31,928 (0.3)	128/29,842 (0.4)	68/3,757 (1.8)
<i>Rash<sup>e</sup></i>	8/4,679 (0.2)	58/32,420 (0.2)	91/30,136 (0.3)	20/4,016 (0.5)
<i>Vomiting<sup>c</sup></i>	3/4,611 (0.1)	39/31,924 (0.1)	48/29,838 (0.2)	19/3,756 (0.5)
<i>Diarrhea<sup>c</sup></i>	7/4,613 (0.2)	42/31,931 (0.1)	57/29,839 (0.2)	13/3,755 (0.3)
<i>Rigors<sup>f</sup></i>	5/4,667 (0.1)	39/32,287 (0.1)	45/29,947 (0.2)	4/3,760 (0.1)
<i>Non-responsiveness/loss of consciousness<sup>c</sup></i>	0/4,611 (0.0)	1/31,920 (0.003)	2/29,833 (0.007)	0/3,755 (0.0)
<i>Convulsions/seizures<sup>g</sup></i>	0/4,679 (0.0)	1/32,420 (0.003)	1/30,136 (0.003)	0/4,016 (0.0)
<i>Other<sup>h</sup></i>	40/4,679 (0.9)	255/32,420 (0.8)	286/30,136 (0.9)	61/4,016 (1.5)

Median age for each brand (interquartile range): Afluria Quad: 63 years (47–71 years), Fluarix Tetra: 65 years (45–71 years), FluQuadri: 51 years (29–66 years), FluQuadri Junior: 1 year (1–2 years)

<sup>a</sup> Vaccine brand could not be determined for 196 participants (0.3%), who were excluded from this analysis.

<sup>b</sup> Denominators differ between adverse events because symptoms are solicited in an online survey following the initial SMS regarding an AEFI, and not all participants complete the survey.

<sup>c</sup> Collected by SmartVax only.

<sup>d</sup> SmartVax and STARSS collect data on injection site swelling and/or redness in one question, while Vaxtracker has separate questions for injection site redness and injection site swelling. The Vaxtracker data for injection site redness and injection site swelling have been combined for this table.

<sup>e</sup> STARSS specifies that the rash is over a large area of the body.

<sup>f</sup> SmartVax includes a description (“shaking or shivering with high temperature”), while STARSS and Vaxtracker do not refer to rigors and instead collect data on “chills and shakes”.

<sup>g</sup> SmartVax collects data on “convulsions/seizures”, while Vaxtracker collects information on “seizures”, and STARSS collects information on “seizures or fits”.

<sup>h</sup> A free-text response box is provided for participants responding that they had an “Other” reaction to describe the event(s).